Equity markets have faced downward pressure over the past three weeks, raising concerns about a potential prolonged downturn amid ongoing global trade tensions and geopolitical uncertainties. However, opportunities may lie in identifying undervalued stocks with solid long-term growth prospects, such as CVS Health and AbbVie, both of which have recently experienced share price declines.
CVS Health is grappling with challenges related to Medicare Advantage payment rates and rising costs, leading to a post-earnings sell-off. Despite these hurdles, the company’s diversified healthcare model and commitment to improving margins position it well for future recovery. On the other hand, AbbVie’s reliance on Humira is waning, yet its promising immunology drugs, Skyrizi and Rinvoq, are projected to drive significant revenue growth. With a robust pipeline and a strong dividend history, AbbVie remains appealing for income-focused investors.
For professionals seeking to navigate this turbulent market, both CVS Health and AbbVie present compelling buying opportunities. I encourage you to explore the full analysis in the original article for deeper insights.
Source: fool.com